Ibogaine Therapy Mexico
Ibogaine Therapy Mexico · Research & Data

26 Ibogaine Statistics & Veteran Mental Health Facts for 2026

A research-backed reference for journalists, clinicians, policymakers, and veterans. Every statistic is drawn from peer-reviewed studies, federal agency reports, or verified institutional data — with primary sources linked for each entry.

Last updated April 2026. Click any statistic to expand the full context and source citation.

26 Statistics5 CategoriesPrimary Sources LinkedUpdated April 2026

Veteran Mental Health Crisis

5 stats

Before you can understand why veterans are flying to Mexico for ibogaine treatment, you need to sit with these numbers for a moment. This isn't a population that hasn't tried conventional care — it's one that conventional care has largely failed. The psychedelic therapy for veterans statistics that follow aren't abstractions. They describe real people who ran out of options.

17.6
veterans die by suicide every day in the United States
►Click for context & source
›
22%
of all U.S. suicides involve veterans — who are only 7% of the adult population
►Click for context & source
›
30%
of combat-deployed veterans develop PTSD
►Click for context & source
›
57%
of veterans with PTSD don't respond to first-line treatments
►Click for context & source
›
1 in 4
veterans self-medicate PTSD symptoms with illicit substances
►Click for context & source
›

Ibogaine Clinical Research

7 stats

The Stanford ibogaine study on veterans — published in Nature Medicine in February 2024 — is the most rigorous peer-reviewed research on ibogaine PTSD treatment outcomes to date. These aren't anecdotes. These are controlled measurements with validated psychiatric scales, tracked before and after a single treatment session. The numbers are remarkable enough that they were cited by President Trump at the April 2026 executive order signing.

88%
average reduction in PTSD severity — Stanford ibogaine study, 2024
►Click for context & source
›
87%
reduction in depression scores one month post-treatment
►Click for context & source
›
81%
reduction in anxiety severity scores at one-month follow-up
►Click for context & source
›
0
serious cardiac events in the Stanford trial — with proper magnesium protocol
►Click for context & source
›
30.2 → 5.1
WHO disability score before and after treatment — from moderate disability to none
►Click for context & source
›
12–36
hours: how long an ibogaine treatment session actually lasts
►Click for context & source
›
60%
of opioid-dependent patients reported no significant withdrawal symptoms after ibogaine
►Click for context & source
›

Ibogaine & the Opioid Crisis

4 stats

Ibogaine's history in addiction research predates the PTSD conversation by decades. It first came to scientific attention in the 1980s and 90s specifically as a potential treatment for opioid dependence — with a mechanism unlike anything in the existing pharmacopeia. The opioid crisis has given that original research new urgency. These statistics put the scale of the problem in context.

80,000+
Americans died from opioid overdose in 2023
►Click for context & source
›
40–60%
relapse rate for opioid use disorder within the first year of standard treatment
►Click for context & source
›
75%
of opioid-dependent patients maintained abstinence 3 months after ibogaine — early trials
►Click for context & source
›
$35B+
annual economic cost of opioid use disorder in the United States
►Click for context & source
›

Policy, Funding & the Road to FDA Approval

6 stats

Ibogaine went from a fringe topic to the Oval Office in roughly three years. The Netflix documentary In Waves and War, the Stanford Nature Medicine study, and sustained advocacy from veteran organisations built the political conditions for federal action. Here's where things actually stand — without the hype.

April 18, 2026
Trump signs ibogaine executive order — the first federal action of its kind
►Click for context & source
›
$50M
committed by Texas in 2025 for ibogaine clinical research
►Click for context & source
›
51–1
Mississippi Senate vote in favor of $5M ibogaine research bill, March 2026
►Click for context & source
›
1,200+
veterans funded for ibogaine treatment by VETS — with 9 in 10 applicants turned away
►Click for context & source
›
2–4 years
realistic minimum timeline to FDA approval — even with fast-track review
►Click for context & source
›
$6.9B
projected global psychedelic medicine market by 2027
►Click for context & source
›

Ibogaine Treatment in Mexico: Practical Facts

4 stats

Mexico is where Americans actually go for ibogaine treatment today — not as a workaround, but because the clinical infrastructure is there and the legal environment permits it. These are the practical facts about ibogaine therapy cost in Mexico, legal status, and what to expect from a medically serious program.

Legal
ibogaine status under Mexican federal law — not a controlled substance
►Click for context & source
›
$3K–$15K
ibogaine therapy cost in Mexico — what treatment actually costs
►Click for context & source
›
5–14 days
typical program length at reputable ibogaine clinics in Mexico
►Click for context & source
›
ECG required
at every reputable ibogaine clinic — non-negotiable cardiac screening
►Click for context & source
›

Ibogaine is one of several plant medicines under active study for addiction and trauma. For comparative statistics covering psilocybin, ayahuasca, and 5-MeO-DMT and other plant-based recovery pathways, see our sister site's research compilation.

Citing These Statistics

Journalists, researchers, and bloggers are welcome to cite individual statistics from this page. Please link to the primary source listed with each statistic, and credit this compilation as follows:

Ibogaine Therapy Mexico, Ibogaine Statistics & Veteran Mental Health Facts 2026, ibogainetherapymexico.org/ibogaine-statistics-2026

Medical Disclaimer: This page is for informational and research purposes only. Ibogaine is a Schedule I controlled substance in the United States. Nothing on this page constitutes medical advice. Anyone considering ibogaine therapy should consult qualified medical professionals and ensure any treatment is conducted in a fully medically supervised setting.